Proteins and Peptides

17 Jan 2019 Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019
12 Jan 2019 Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
10 Jan 2019 Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
07 Jan 2019 Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
03 Jan 2019 First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors
27 Dec 2018 Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
22 Dec 2018 FDA approves longer-acting calaspargase pegol-mknl for ALL
20 Dec 2018 AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
20 Dec 2018 Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
20 Dec 2018 Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes
19 Dec 2018 PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
19 Dec 2018 Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial Dec
17 Dec 2018 Cerenis Therapeutics: Final Results of TARGET PHASE II Study Demonstrate the Ability of CER-001, an HDL Mimetic, to Target Tumor in Patients with Esophageal Cancer
14 Dec 2018 Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
14 Dec 2018 Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
12 Dec 2018 Levo Therapeutics Announces Initiation of the CARE-PWS Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
11 Dec 2018 Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
11 Dec 2018 Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes That CollPlant's Vergenix™ STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow
09 Dec 2018 Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
05 Dec 2018 CERENIS Announces the Results of TANGO, a Phase III Clinical Study Evaluating CER-001 in Patients with HDL Deficiency
04 Dec 2018 Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
04 Dec 2018 Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
03 Dec 2018 Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
29 Nov 2018 Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
28 Nov 2018 Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up